La taille du marché des produits thérapeutiques contre le glaucome devrait atteindre 8,02 milliards de dollars américains d'ici 2031, contre 6,24 milliards de dollars américains en 2023. Le marché devrait enregistrer un TCAC de 3,2 % en 2023-2031. Le développement de nouvelles méthodes d'administration de médicaments et de thérapies combinées restera probablement une tendance clé sur le marché des produits thérapeutiques contre le glaucome.
Analyse du marché des produits thérapeutiques contre le glaucome< /h3>
Le glaucome est un groupe de troubles oculaires caractérisés par une perte progressive de tissu nerveux qui pourrait éventuellement conduire à une perte de vision si elle n'est pas traitée. Les analogues des prostaglandines font partie des médicaments très efficaces pour réduire la pression oculaire en favorisant un meilleur drainage oculaire. La prévalence croissante du glaucome et l'augmentation des lancements de produits devraient favoriser la croissance du marché des produits thérapeutiques contre le glaucome.
Aperçu du marché des produits thérapeutiques contre le glaucome
Le vieillissement de la population mondiale a entraîné une incidence croissante du glaucome, créant ainsi une opportunité significative pour la croissance du marché du traitement du glaucome. La demande de thérapies et de stratégies de gestion innovantes augmente en raison de la plus grande susceptibilité de la population vieillissante à la maladie. De plus, l’importance de contrôles oculaires réguliers pour la détection précoce et la prise en charge du glaucome a accru l’engagement des patients et la demande de traitements avancés. Alors que les systèmes de santé répondent aux besoins d'une population vieillissante, les investissements dans la recherche, le développement et l'accès aux soins sur le glaucome devraient alimenter la croissance du marché dans les années à venir.
Glaucoma Therapeutics Moteurs et opportunités du marché
La maladie du glaucome augmente pour favoriser le marché
Selon la Glaucoma Research Foundation, en 2022, ~ 80 Des millions de personnes ont été atteintes de glaucome dans le monde. En 2010, près de 8,4 millions de personnes dans le monde avaient perdu la vue à cause d’un glaucome primitif à angle ouvert. Selon la Glaucoma Research Foundation, ce nombre devrait atteindre 22 millions d'ici 2040. Cela devrait augmenter la demande de traitements contre le glaucome dans la période à venir. L'augmentation de l'incidence du glaucome au sein de la population mondiale est un moteur majeur du marché mondial des traitements contre le glaucome.
Aperçus stratégiques
Développement des technologies portables - Une opportunité de personnalisation des traitements contre le glaucome
Le glaucome est une cause majeure de cécité, et une détection et un traitement précoces sont essentiels. Les diagnostics et traitements portables du glaucome sont apparus comme des solutions potentielles. Les techniques de diagnostic conventionnelles fournissent des données fiables sur la pression intraoculaire, mais les lentilles de contact émergentes telles que Sensimed Triggerfish offrent un suivi continu de la PIO. Pour le traitement, les lentilles de contact à élution médicamenteuse apparaissent comme une solution potentielle. Les plateformes théranostiques combinent des capacités diagnostiques et thérapeutiques dans un seul appareil pour offrir une surveillance en temps réel et un dosage personnalisé des médicaments.
Analyse de segmentation du rapport sur le marché thérapeutique du glaucome
Les segments clés qui ont contribué à l'analyse du marché des produits thérapeutiques contre le glaucome sont la classe de médicaments, l'indication et canal de distribution.
- Basé sur classe de médicament< span>, le marché thérapeutique du glaucome est divisé en bêtabloquants, agonistes alpha-adrénergiques, analogues de prostaglandines, inhibiteurs de l'anhydrase carbonique, médicaments combinés et autres. Le segment des analogues de prostaglandines détenait la plus grande part de marché en 2023.
- Le marché est segmenté par indication en glaucome à angle ouvert, glaucome à angle fermé et autres. Le segment du glaucome à angle ouvert détenait la plus grande part du marché en 2023.
- En termes de canal de distribution, le marché est segmenté en pharmacie hospitalière, pharmacie de détail et pharmacie en ligne. Le segment des pharmacies hospitalières a dominé le marché en 2023.
Analyse de la part de marché des produits thérapeutiques contre le glaucome par géographie
La portée géographique du Le rapport sur le marché des produits thérapeutiques contre le glaucome est principalement divisé en cinq régions : Amérique du Nord, Asie-Pacifique, Europe, Moyen-Orient et Amérique du Nord. Afrique et Afrique du Sud et Amérique centrale.
En 2022, près de 2,7 millions d'Américains ont été touchés par le glaucome à angle ouvert ; Le glaucome était la principale cause de cécité irréversible aux États-Unis. En raison de l'incidence croissante du glaucome dans la région, l'Amérique du Nord détenait la plus grande part en 2022. La propension croissante aux nouvelles thérapies combinées et aux traitements du glaucome mini-invasifs ainsi que la présence d'acteurs clés du marché en Amérique du Nord sont des facteurs contribuant à la croissance du glaucome. marché thérapeutique dans la région.
Actualités et développements récents du marché thérapeutique du glaucome
Le marché thérapeutique du glaucome est évalué en collectant des données qualitatives et quantitatives après la recherche primaire et secondaire, qui comprennent d'importantes publications d'entreprise, des données d'association et des bases de données. Voici une liste des développements sur le marché des traitements contre le glaucome :
- La Food and Drug Administration (FDA) des États-Unis a approuvé le nouveau produit de Glaukos Corporation. Demande de médicament (NDA) pour une administration unique par œil d'iDose TR (implant intracaméral de travoprost) 75 mcg, un analogue de la prostaglandine indiqué pour la réduction de la pression intraoculaire (PIO) chez les patients souffrant d'hypertension oculaire (OHT) ou de glaucome à angle ouvert (OAG ). (Source : Glaukos Corporation, Company News, 2023)
- Alcon a annoncé l'acquisition d'Aerie Pharmaceuticals, Inc. Dans le cadre de la transaction, la société a acquis Rocklatan (solution ophtalmique de nétarsudil et de latanoprost) 0,02 %/0,005 % et Rhopressa (solution ophtalmique nétarsudil) 0,02 %, ainsi que AR-15512, un produit candidat de phase 3 pour la sécheresse oculaire, et un portefeuille de plusieurs produits pharmaceutiques ophtalmiques cliniques et précliniques. Rocklatan et Rhopressa sont des inhibiteurs de la Rho-kinase indiqués pour la réduction de la PIO élevée chez les patients atteints de glaucome à angle ouvert ou d'hypertension oculaire. Cette acquisition devrait élargir le portefeuille d'Alcon dans les domaines du glaucome, de la rétine et des maladies de la surface oculaire. (Source : Alcon, communiqué de presse, 2022)
Couverture et livrables du rapport sur le marché des produits thérapeutiques contre le glaucome
Les produits thérapeutiques contre le glaucome Taille et prévisions du marché (2021-2031) » Le rapport fournit une analyse détaillée du marché couvrant les domaines ci-dessous :
- Taille et prévisions du marché aux niveaux mondial, régional et national pour tous les segments de marché clés couverts par le portée
- Dynamique du marché telle que les moteurs, les contraintes et les opportunités clés
- Principales tendances futures
- Analyse détaillée PEST et SWOT
- Analyse du marché mondial et régional couvrant les principales tendances du marché, les principaux acteurs, les réglementations et les évolutions récentes du marché
- Analyse du paysage industriel et de la concurrence couvrant la concentration du marché et la carte thermique analyse, acteurs de premier plan et développements récents
- Profils d'entreprise détaillés
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The glaucoma therapeutics market by drug class, is divided into beta blockers, alpha-adrenergic agonists, prostaglandin analogs, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandin analogs segment held a larger market share in 2023.
The glaucoma therapeutics informatics was valued at US$ 6.24 billion in 2023.
Key factors driving the glaucoma therapeutics informatics growth are the surging prevalence of glaucoma and increasing product launches.
The glaucoma therapeutics market majorly consists of the players, including Inoteck Pharmaceuticals; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Santen Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company; AstraZeneca PLC; AERIE Pharmaceuticals, Inc.; and Cipla Inc.
Glaucoma is a group of eye disorders characterized by the gradual loss of nerve tissue that would eventually lead to vision loss if left untreated. Prostaglandin analogs are among the drugs that are highly effective in reducing eye pressure by promoting better drainage from the eye.
The glaucoma therapeutics market is expected to be valued at US$ 8.02 billion in 2031.
The List of Companies - Glaucoma Therapeutics Market
- Fera Pharmaceuticals
- GlaxoSmithKline plc
- Bristol Myers Squibb
- Eli Lilly and Company
- Amgen
- MannKind Corporation
- Sangamo Therapeutics
- SciClone Pharmaceuticals, Inc.
- Critical Therapeutics, Inc.
- Takeda Pharmaceutical Company
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Apr 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Apr 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Apr 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)